Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- China Medical Reports Positive Results for Ongoing Business
- ChinaBio Today submits: As promised earlier, China Medical Technologies CMED released selected Q2 (ended September 30, 2008) results, though a full disclosure, complete with analysts’ call, will wait until December 18. The problem with a full release is reporting issues: China Medical is deciding how to account for its...
- External links 2008-11-18
- Tongjitang Shares React Well to Buyback News
- ChinaBio Today submits: Tongjitang Chinese Medicines Company TCM announced its shareholders approved a $20 million share buyback program at the company’s general meeting. The resolution calls for the company to complete a purchase of “up to” $20 million worth of its ADSs within the next 18 months. The program...
- External links 2008-11-04
- 3SBio's Q3 Hurt by Lehman Bankruptcy
- ChinaBio Today submits: 3SBio Inc. SSRX announced a $2.7 million writedown as a consequence of the U.S. financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers...
- External links 2008-11-04
- China Medical Wrestles with Daunting $345 Million Acquisition
- ChinaBio Today submits: China Medical Technologies CMED told investors it would release a preliminary Q2 (ended September 30, 2008) financial report on November 18, but a full announcement, complete with answering questions from analysts, will wait another month until December 18. As reason for the delay, the company said...
- External links 2008-10-27
- WuXi Misses Q3 Forecast, Guides Lower for Year
- ChinaBio Today submits: WuXi PharmaTech WX released weaker-than-expected financial Q3 results unaudited and, at the same time, lowered guidance for its full year. The company reduced its forecast for 2009 revenue by $20 to $35 million. The new revenue range is expected to be between $260 and $265 million,...
- External links 2008-10-15
- Investors Liked What They Saw in Simcere's Q3 Report
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4...
- External links 2008-11-06
- Genesis Pharma Reports Improved Q1
- ChinaBio Today submits: Genesis Pharmaceuticals Enterprises, Inc. (GNPH.OB) reported that Q1 (ended September 30, 2008) revenues climbed an admirable 66% to $27.6 million, and gross profit rose an even more dramatic 81% to $21.8 million. On a non-GAAP basis, Genesis reported net income of $4.8 million a 50% increase....
- External links 2008-11-18
- BMP Sunstone's Q3: Revenues on the Rise
- ChinaBio Today submits: BMP Sunstone Corporation BJGP, a company that has been building itself through acquisitions over the last two years, announced very strong Q3 results. It was the first quarter in which results included participation from BMP Sunstone’s acquisition of drug distributor Rongheng. Sunstone announced it acquired a...
- External links 2008-11-12
- Mindray's Q3 Leaves Investors Less Than Pleased
- ChinaBio Today submits: On the face of it, the Q3 financial report issued by Mindray Medical International MR was very positive. Revenues were up 94% at $146.5 million and non-GAAP net income climbed a smaller but still respectable 48% to $33.7 million. Nevertheless, Mindray’s stock price suffered in the...
- External links 2008-11-11
Additional Resources
- China Shenghuo's Revenues Can't Keep Up with Expenses
- ChinaBio Today submits: China Shenghuo Pharmaceutical Holdings KUN has resumed trading on the NYSE Alternext US exchange. In early action, the price of its shares was cut in half, dropping 98 cents (52%) to $.91. The company’s stock was suspended from trading in late August because China...
- External links 2008-12-10
- << Previous
- page 1 of 1
- Next >>
Presented by American Express